Navigation Links
Highmark Study Shows Integrated Medical and Pharmacy Benefits Lower Costs, Promote Better Health

PITTSBURGH, June 2 /PRNewswire/ -- At a time when employers are seeking innovative ways to control medical benefits expenses, a study from Highmark Inc. has revealed that the integration of medical and pharmacy benefits lowers overall medical costs, while promoting better health.

In an effort to save on health benefits costs, some employers choose a "carve-out" model by contracting with a pharmacy benefits manager to provide its prescription drug benefit. Highmark's study, which was published in Benefits & Compensation Digest, shows that an integrated medical and prescription drug benefit, however, has the potential to provide greater savings to group customers.

Highmark analyzed clients that carve out pharmacy benefits for their employees and compared them to Highmark's customers who have an integrated medical and prescription drug benefit.

"The findings showed that during the four-year period of the analysis, annual medical expenses for our group customers averaged 6.2 percent lower for customers who carve in the pharmacy prescription drug benefit versus those who do not," said Dr. Eric Culley, manager of clinical pharmacy services at Highmark. "Therefore, for a group of 1,000 employees, that equates to an approximate $549,260 in medical cost avoidance during a four-year period. For the same timeframe, customers with an integrated medical and prescription drug benefit experienced an annual average of 15.8 percent less in outpatient expenses and 7.7 percent less in emergency room expenses for their employees."

"The study provides evidence that validates that the integration of Highmark's medical and pharmacy benefits promotes better health and lowers overall medical costs," said Dr. Donald Fischer, Highmark's chief medical officer. "By using pharmacy claims data, we are able to identify members who have chronic conditions and provide physicians and members access to information that can help them more effectively manage their diseases."

In fact, 43 percent of Highmark members with asthma, 41 percent with diabetes and about 30 percent of members with chronic obstructive pulmonary disease (COPD) have been identified as having chronic conditions based on pharmacy claims.

"If those members with chronic conditions had their pharmacy benefit carved out, it would have been difficult for us to identify their disease and get them the help they need in managing it," said Fischer.

About Highmark Inc.

As one of the leading health insurers in Pennsylvania, Highmark Inc.'s mission is to provide access to affordable, quality health care enabling individuals to live longer, healthier lives. Based in Pittsburgh, Highmark serves 4.7 million people through the company's health care benefits business. Highmark contributes millions of dollars to help keep quality health care programs affordable and to support community-based programs that work to improve people's health. Highmark exerts an enormous economic impact throughout Pennsylvania. A recent study states that Highmark's positive impact exceeded $2.5 billion. The company provides the resources to give its members a greater hand in their health.

Highmark Inc. is an independent licensee of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. For more information, visit

SOURCE Highmark Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Highmark Presents Work on MRSA Prevention at National Health Care Quality Conference
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
8. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
9. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
10. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
11. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
Post Your Comments:
(Date:11/24/2015)... CHICAGO , Nov. 24, 2015  Figure 1, ... view and share medical cases, has launched a new ... of the web version allows radiologists, who work primarily ... workstation. To further engage with its radiologist user base, ... Society of North America (RSNA) ...
(Date:11/24/2015)... , Nov. 24, 2015 Teledyne DALSA , ... image sensing technology, will introduce its CMOS X-Ray detector ... , November 29 to December 3, at McCormick Place in ... detectors for diagnostic and interventional imaging will be on display ... family of advanced CMOS X-Ray detectors is the industry ...
(Date:11/24/2015)... Nov. 24, 2015  NuShield, Inc., an industry leader in LCD screen protection and glare-elimination technology, ... technology as part of their patient monitoring or electronic documentation system. ... ... ... A study in 2013 ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... ThirdLove, the fast-growing bra company ... early, offering 40% off select bras and underwear styles, now through Saturday, November ... fit technology and the latest fashion, quickly becoming the next generation of luxury ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... leaders when it comes to several aspects of orthopedic care. They have received ... orthopedic surgeries and general orthopedic care. , Becker's Hospital Review selected hospitals ...
(Date:11/24/2015)... Berkeley, California (PRWEB) , ... November 24, 2015 ... ... Brillouin Energy's LENR HHT Bolier Reactor System. Brillouin is the developer of renewable ... on controlled low energy nuclear reactions (“LENR”), announced today that its WET™ and ...
(Date:11/24/2015)... VA (PRWEB) , ... November 24, 2015 , ... ... people across the United States to support their local poison centers through donations ... designated as #GivingTuesday: calls it “a day that inspires people to collaborate ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the Ron ... designed to yield insights into how to detect and treat pancreatic cancer (PC). ... from small, non-coding RNA molecules (ncRNA), genetic material that is present in the blood ...
Breaking Medicine News(10 mins):